Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer
|
|
- Mary Malone
- 6 years ago
- Views:
Transcription
1 Ann Thorac Cardiovasc Surg 2011; 17: Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu Hikosaka, MD, and Yoshitaka Fujii, MD Purpose: In pathologic IB (pib) non-small cell lung cancer, especially in adenocarcinoma, adjuvant chemotherapy with uracil-tegafur is widely recognized as being effective. The aim of this study was to determine the prognostic factors of pib disease. Patients and Methods: Sixty patients who were diagnosed with pib disease between 2004 and 2007 were retrospectively analyzed. Results: Of 60 patients, 22 (36.7%) opted for surgery plus adjuvant chemotherapy with uracil-tegafur, whereas 38 (63.3%) opted for surgery only. The oral administration dose of uracil-tegafur was 400 mg/body. Compliance of adjuvant chemotherapy with uracil-tegafur was 65.5% in 12 months, 57.3% in 24 months. Adjuvant chemotherapy was interrupted in 11 patients because of the recurrence of disease in 3 patients and adverse reaction in 8 patients. Anorexia was the most common adverse reaction. The larger tumor diameter (5cm<) and p2 pleural invasion were the worse prognostic factors in disease free survival in a univariate analysis and a multivariate analysis (hazard ratio = 0.26 and 0.25; p = and 0.032, respectively). Conclusion: The prognosis of the patients with pleural invasion and a tumor diameter >5cm was poor, and these, partly support the forthcoming classification. Key words: lung cancer, adjuvant chemotherapy, tegafur Introduction Adjuvant chemotherapy has been proven to be beneficial for survival in patients with resected non-small cell lung cancer (NSCLC). 1 3) Uracil-tegafur has been approved for the treatment of patients with NSCLC and Departments of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan Received: July 10, 2009; Accepted: October 8, 2009 Corresponding author: Motoki Yano, MD. Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi , Japan motoki@med.nagoya-cu.ac.jp 2011 The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery. All rights reserved. extensively examined for use in adjuvant chemotherapy in Japan. It has been shown that surgery and adjuvant chemotherapy with uracil-tegafur provided a survival advantage over only surgery. 4 7) Especially in patients with pathologic stage IB adenocarcinoma, the efficacy of adjuvant chemotherapy with uracil-tegafur was higher than in the other stages. However, pathological IB disease has been recognized as heterogeneous. In the forthcoming edition of staging classification for lung carcinoma by International Association for the Study of Lung Cancer (IASLC) (version 7), the present pathologic stage IB disease will be classified into pib, piia, and piib according to the maximum diameter of the tumor. 8) Since the stage classification is being revised, a review of the former evidence is necessary. The aim of this study was to determine the prognostic factors of pib disease. 58 Ann Thorac Cardiovasc Surg Vol. 17, No. 1 (2011)
2 Pathologic Stage IB Non-small Cell Lung Cancer Patients and Methods Patients and Treatment We reviewed surgically resected patients with lung carcinoma who were treated at Nagoya City University Hospital between January 2004 and December 2007 and 61 patients were diagnosed with pathologic stage IB disease underwent complete tumor resection. One patient who received postoperative adjuvant therapy uracil-tegafur was excluded from the study, and the remaining 60 patients were eligible for this study. All 60 patients were given an explaination about the predicted benefit and adverse reactions of adjuvant therapy with uracil-tegafur. Permission from the institutional review board and informed consent from each patient were obtained. The daily oral administration dose was 400 mg per body, and treatment was initiated within 1 month postoperatively. Administration of uracil-tegafur for 2 years was regarded as complete, and patients were allowed to take the drug for up to 2 years. Adverse events arising from adjuvant chemotherapy were identified from the medical records and graded according to the Common Terminology Criteria for Adverse Events version 3.References Statistical Analyses Disease free survival was used to evaluate the efficacy of adjuvant chemotherapy of uracil-tegafur. The differences of significance among categorized groups were compared using χ 2. Univariate and multivariate analyses of disease-free survival were carried out with the Kaplan-Meier method using the log-rank test and the Cox proportional hazards model, respectively. All statistical tests were two sided, and p<0.05 was considered statistically significant. Results Patient and clinicopathological characteristics The patient characteristics were as follows. The median age was 69 years (range, 21 to 85 years); 35 patients were male, and 25, female. Thirty-six patients were current or former smokers, and 24 patients had never smoked. Most common histopathological types were adenocarcinoma (n = 36) and squamous cell carcinoma (n = 15). Nine patients were diagnosed as having other histological types or combined types with adenocarcinoma and other histological types. The maximal tumor diameter was within 5 cm in 48 patients and over 5 cm in 12 patients. Obvious tumor invasion of the visceral pleura (p2) was observable in 8 patients. Epidermal growth factor receptor (EGFR) gene mutation status was analyzed in 57 tumors. Detail procedures of EGFR gene mutation analysis have been reported previously. A point mutation of L858R in exon 21 was found in 6 cases. Several types of deletion mutants in exon 19 were found in these 8 cases. The other 43 tumors were wild type of the EGFR gene. Compliance, survival and adjuvant chemotherapy with uracil-tegafur All 60 patients received an explanation about the predicted benefit and adverse reactions of adjuvant therapy with uracil-tegafur. Of 60 patients, 22 (36.7%) consented to take uracil-tegafur as adjuvant chemotherapy, whereas 38 (63.3%) did not consent and underwent surgery only. The background of patients with or without adjuvant therapy with uracil-tegafur is shown in Table 1. In the group with adjuvant chemotherapy, the ratios of younger and female patients were higher. Also, the EGFR gene mutation was often found. Compliance of adjuvant chemotherapy with uraciltegafur was calculated excluding 3 patients with a recurrence of disease. The rate of compliance was 71.4% in 6 months, 65.5% in 12 months, and 57.3% in 24 months (Fig. 1). Seven patients completed the 2-year regimen of adjuvant chemotherapy. Administration was continuing and not completed in 4 patients. Adjuvant chemotherapy was stopped in 11 patients because of the recurrence in 3 patients and adverse reaction in 8 patients. Anorexia was the most common adverse reaction and graded 1 in 3 patients and graded 2 in 2 patients. Other adverse reactions were grade 2 serum glutamic oxaloacetic transaminase elevation in 1 patient, grade 2 rash in 1 patient, and grade 2 pneumonitis in 1 patient. By December 2008, 7 (11.7%) of 60 patients (2 with adjuvant chemotherapy and 5 with surgery alone) had died, with a median follow-up time among the surviving patients of 24.7 months for the adjuvant chemotherapy group and 23.9 months for the control group. Overall survival was 85.8% in 2 and 4 years after the operation. Disease free survival was 85.4% in 2 years and 70.5% in 4 years. Clinicopathological factors that influenced prognosis were analyzed (Table 1); gender, age, pathological type, and EGFR gene mutation status, did not significantly alter the prognosis. Adjuvant chemotherapy of uracil- Ann Thorac Cardiovasc Surg Vol. 17, No. 1 (2011) 59
3 Yano M et al. Table 1 Univariate analysis of prognostic factors in patients characteristics. Characteristics No. of patients 2-years disease p free survival (%) Age < Gender Male Female Pathological types adenocarcinoma other types Tumor diameter <5cm cm Pleural invasion p p Adjuvant chemotherapy In the selected 41 patients with both smaller diameter ( 5cm) and p0 or p1 pleural factor, the disease free survival of the group with adjuvant chemotherapy of uraciltegafur was better compared to the group who had only surgery; however, the difference did not reach statistical significance (p = 0.504, not shown). Discussion Fig. 1 Kaplan-Meier plot of compliance of uracil-tegafur in 22 patients. tegafur did not improve the prognosis in relation to any of these. The larger tumor diameter (5cm<) (Fig. 2) and p2 pleural invasion (Fig. 3) were factors for a poor prognosis in disease free survival in a univariate analysis (p = and 0.019, respectively). To compare p0 vs. p1 and p2, we found that there was no difference in disease free survival (p = 0.229). In a multivariate analysis, a larger tumor diameter (5cm<) and p2 pleural invasion were independent factors for a poor prognosis (hazard ratio = 0.26 and 0.25; 95% CI, 0.08 to 0.86 and 0.07 to 0.89; p = and 0.032, respectively). In pathologic IB non-small cell lung cancer, especially in adenocarcinoma, adjuvant chemotherapy with uraciltegafur has been widely recognized as being effective. In a previous study, Kato et al. reported that adjuvant chemotherapy with uracil-tegafur improved overall survival in stage I adenocarcinoma, especially in T2 disease. 6) The hazard ratio was 0.48 for the T2N0 adenocarcinoma of patients who received uracil-tegafur. Park et al. reported that adjuvant chemotherapy with uracil-tegafur improved disease-free survival. 9) In the present study, we have shown a low compliance of adjuvant chemotherapy with uracil-tegafur. Kato et al. reported that the compliance of uracil-tegafur in 498 patients was 61% in 24 months. 6) The compliance of uracil-tegafur in our patients was similar (57.5%). They reported a low rate of severe adverse reactions as we did. The main adverse reactions were anorexia and nausea, thus, patients lost their motivation to continue treatment and compliance fell to around 60%. In daily medical treatment, we should rec- 60 Ann Thorac Cardiovasc Surg Vol. 17, No. 1 (2011)
4 Table 2 Multivariate analysis of prognostic factors Variable HR 95% CI p Tumor diameter <5cm vs 5cm to Pleural invasion p0+1 vs p to Pathologic Stage IB Non-small Cell Lung Cancer Fig. 2 Disease free survival of all 60 patients stratified by maximal tumor diameter status. Fig. 3 Disease free survival of all 60 patients stratified by visceral pleural invasion status. ognize these facts anew and we have to encourage the patients to continue adjuvant chemotherapy with maintenance of their motivation. We have also shown the heterogeneity of pib disease in prognosis. The patients with both smaller diameter (T 5cm) and p0 or p1 pleural factor had a better prognosis. In the forthcoming IASLC staging classification, patients with a larger tumor diameter (5cm<T) will be classified into stage IIA or IIB. 8) Our data supports the new classification. Park et al. reported prognostic factors for disease free survival in completely resected pt2n0 non-small cell lung cancer, 9) and they also proposed that visceral pleural invasion was an independent poor prognostic factor, which our data also confirms.. It is easy to imagine that patients with clinopathological factors such as a larger tumor diameter (5cm<T) or p2 pleural invasion require the more powerful platinum-based regimen of adjuvant chemotherapy. In the efficacy of adjuvant chemotherapy with uraciltegafur, molecular biological analysis has been reported. Suehisa et al reported that the EGFR mutation status influenced the clinical benefit of adjuvant chemotherapy with uracil-tegafur in patients with resected lung adenocarcinoma. 10) Adjuvant chemotherapy with uracil-tegafur in the patients with EGFR wild-type was more effective than in patients with the same EGFR wild-type who had only surgery, and they could not show efficacy of adjuvant chemotherapy with uracil-tegafur in the patients Ann Thorac Cardiovasc Surg Vol. 17, No. 1 (2011) 61
5 Yano M et al. with an EGFR mutation. In another biological analysis, Miyoshi et al. reported a relation between the efficacy of uracil-tegafur and thymidylate synthase (TS). 11) Adjuvant chemotherapy with uracil-tegafur might improve the survival of NSCLC patients when TS levels in tumor tissues are low. In a study of colorectal cancer, Ogata et al. reported that matrix metalloproteinase 9 (MMP-9) decreased the effect of uracil-tegafur. 12) Tanaka et al. reported that postoperative adjuvant therapy for NSCLC had a larger effect on the prolonged survival of patients with tumors having a high apoptotic index compared to patients with tumors having a low apoptotic index. 13) In further studies, an appropriate combination of clinical and molecular biological analyses may determine which patient population might benefit the most from adjuvant chemotherapy. In conclusion, the prognosis of the patients with a tumor diameter >5cm and pleural invasion was poor, and these facts partly support the forthcoming classification. References 1) Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, et al. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: ) Winton T, Livingston R, Johnson D, Rigas J, Johnston M, et al. National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR.10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected nonsmall-cell lung cancer. N Engl J Med 2005; 352: ) Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: ) Tanaka F, Miyahara R, Ohtake Y, Yanagihara K, Fukuse T, et al. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg 1998; 14: ) Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, et al. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: Reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: ) Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: ) Hamada C, Tanaka F, Ohta M, Fujimura S, Kodama K, et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 2005; 23: ) Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: ) Park I, Chung KY, Kim KD, Kim DJ. Prognostic factors for disease-free survival in pt2n0 non-small cell lung cancer. Asian Cardiovasc Thorac Ann 2006; 14: ) Suehisa H, Toyooka S, Hotta K, Uchida A, Soh J, et al. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. J Clin Oncol 2007; 25: ) Miyoshi T, Kondo K, Toba H, Yoshida M, Fujino H, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res 2007 ; 27: ) Ogata Y, Matono K, Sasatomi T, Ishibashi N, Ohkita A, et al. The MMP-9 expression determined the efficacy of postoperative adjuvant chemotherapy using oral fluoropyrimidines in stage II or III colorectal cancer. Cancer Chemother Pharmacol 2004; 57: ) Tanaka F, Otake Y, Yanagihara K, Yamada T, Miyahara R, et al. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 2001; 84: Ann Thorac Cardiovasc Surg Vol. 17, No. 1 (2011)
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationIndividualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers
Review Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers Norihiko Ikeda, MD, Seisuke Nagase, MD, and Tatsuo Ohira, MD Several prospective randomized trials
More informationPoor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification
CHEST Original Research Poor Prognostic Factors in Patients With Stage IB Non-small Cell Lung Cancer According to the Seventh Edition TNM Classification LUNG CANCER Ryo Maeda, MD ; Junji Yoshida, MD, PhD
More informationPrognostic impact of intratumoral vascular invasion in non-small cell lung cancer patients
1 Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan 2 Department of Pathology, Research Center for Innovative Oncology, National Cancer Center Hospital East,
More informationPrognosis of recurrent non small cell lung cancer following complete resection
1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI
More informationEvaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution
Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationStage IB Nonsmall Cell Lung Cancers: Are They All the Same?
ORIGINAL ARTICLES: GENERAL THORACIC GENERAL THORACIC SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article,
More informationVisceral pleura invasion (VPI) was adopted as a specific
ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,
More informationAccepted Manuscript. Risk stratification for distant recurrence of resected early stage NSCLC is under construction. Michael Lanuti, MD
Accepted Manuscript Risk stratification for distant recurrence of resected early stage NSCLC is under construction Michael Lanuti, MD PII: S0022-5223(17)32392-9 DOI: 10.1016/j.jtcvs.2017.10.063 Reference:
More informationPulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy
More informationAccepted Manuscript. Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD
Accepted Manuscript Adjuvant Chemotherapy in Stage I Lung Cancer: Is More Better? Chuong D. Hoang, MD PII: S0022-5223(18)31821-X DOI: 10.1016/j.jtcvs.2018.06.069 Reference: YMTC 13198 To appear in: The
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationIs there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer?
Original Article Is there an optimal time to initiate adjuvant chemotherapy to predict benefit of survival in non-small cell lung cancer? Yutao Liu 1*, Xiaoyu Zhai 1*, Junling Li 1, Zhiwen Li 2, Di Ma
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationRESEARCH ARTICLE. Ryosuke Hirano 1, Junji Uchino 1 *, Miho Ueno 2, Masaki Fujita 1, Kentaro Watanabe 1. Abstract. Introduction
RESEARCH ARTICLE Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationApplicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers
European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationPleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma
244 Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma DAISUKE HOKKA 1, KAZUYA UCHINO 2, KENTA TANE 2, HIROYUKI OGAWA
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationAdjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC)
Review Article Adjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC) Ying Liang 1, Heather A. Wakelee 2 1 Department of Medical Oncology, Cancer Center, Sun Yat-sen
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationA feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA nonsmall cell lung cancer
90 ORIGINAL A feasibility study of postoperative adjuvant chemotherapy with fluoropyrimidine S-1 in patients with stage II-IIIA nonsmall cell lung cancer Mitsuhiro Tsuboi 1, Kazuya Kondo 2, Hiromitsu Takizawa
More informationThere has been a growing interest in lung cancer in neversmokers,
ORIGINAL ARTICLE,, and Time of Diagnosis Are Important Factors for Prognosis Analysis of 1499 Never-Smokers with Advanced Non-small Cell Lung Cancer in Japan Tomoya Kawaguchi, MD,* Minoru Takada, MD,*
More informationLung cancer is the most common cause of cancer-related
Original Article Prognostic Factors Based on Clinicopathological Data Among the Patients with Resected Peripheral Squamous Cell Carcinomas of the Lung Tomonari Kinoshita, MD,* Takashi Ohtsuka, MD, PhD,*
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationSleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib
Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department
More informationLocal Recurrence After Surgery for Early Stage Lung Cancer
Original Article Local Recurrence After Surgery for Early Stage Lung Cancer An 11-Year Experience With 975 Patients Chris R. Kelsey, MD 1 ; Lawrence B. Marks, MD 2 ; Donna Hollis, MS 3 ; Jessica L. Hubbs,
More informationIntraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer
Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationResearch Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy
SAGE-Hindawi Access to Research Lung Cancer International Volume 2011, Article ID 152125, 4 pages doi:10.4061/2011/152125 Research Article Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients:
More informationLung cancer is the leading cause of cancer deaths worldwide.
ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationPrognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule
Original Article Prognostic prediction of clinical stage IA lung cancer presenting as a pure solid nodule Jong Hui Suh 1, Jae Kil Park 2, Youngkyu Moon 2 1 Department of Thoracic & Cardiovascular Surgery,
More informationVisceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size
GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,
More informationRole of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer
ONCOLOGY LETTERS 4: 1349-1353, 2012 Role of adjuvant chemotherapy after pneumonectomy for non-small cell lung cancer MENG WANG 1,2, JING ZHAO 3, YAN-JUN SU 1,2, XIAO-LIANG ZHAO 1,2 and CHANG-LI WANG 1,2
More informationThoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationRevisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data
CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.
More informationCurrent outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer
Original Article Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer Tetsuya Mizuno 1, Takaaki Arimura 1, Hiroaki Kuroda 1, Noriaki Sakakura 1, Yasushi
More informationSurvival after Surgery in Stage IA and IB Non Small Cell Lung Cancer
Survival after Surgery in Stage IA and IB Non Small Cell Lung Cancer David Ost 1, Judith Goldberg 2, Linda Rolnitzky 2, and William N. Rom 1 1 Division of Pulmonary and Critical Care Medicine, Department
More informationIn the past two decades, a large number of trials investigated
ORIGINAL ARTICLE Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer Systematic Review and Indirect Comparison Meta-Analysis of Randomized Trials Eric
More informationLymph node metastasis is the most important prognostic
ORIGINAL ARTICLE Differences in the Expression Profiles of Excision Repair Crosscomplementation Group 1, X-Ray Repair Crosscomplementation Group 1, and III-Tubulin Between Primary Non-small Cell Lung Cancer
More informationMOLECULAR AND CLINICAL ONCOLOGY 4: , 2016
774 Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation positive non small cell lung cancer, receiving treatment
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationThe most effective treatment for lung adenocarcinoma is
ORIGINAL ARTICLE Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y. Janjigian, MD,* Bernard J. Park,
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationLung cancer is the leading cause of cancer mortality in the
STATE OF THE ART: CONCISE REVIEW Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer Christopher M. Booth, MD, FRCPC, and Frances A. Shepherd, MD, FRCPC Abstract: Despite improved surgical techniques,
More informationAdenocarcinoma of the lung is the leading cause of cancerrelated
ORIGINAL ARTICLE Prognostic and Therapeutic Implications of EGFR and KRAS Mutations in Resected Lung Adenocarcinoma Jenifer L. Marks, MD,* Stephen Broderick, MD, Qin Zhou, MA, Dhananjay Chitale, MD, Allan
More informationUracil-Tegafur-Induced Pleural Effusion Following Lung Cancer Surgery
Case Report Uracil-Tegafur-Induced Pleural Effusion Following Lung Cancer Surgery Taichiro Goto, MD, 1 Arafumi Maeshima, MD, 2 Yoshitaka Oyamada, MD, 3 Misa Wakaki, MD, 3 Reo Hamaguchi, MD, 3 and Ryoichi
More informationCyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy
Shimizu et al. World Journal of Surgical Oncology (2015) 13:21 DOI 10.1186/s12957-014-0426-0 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Cyclooxygenase-2 expression is a prognostic biomarker
More informationPrognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis
< A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationAdjuvant Chemotherapy for Non-small Cell Lung Cancer
PISA SYMPOSIUM Adjuvant Chemotherapy for Non-small Cell Lung Cancer Emilio Bria, MD, Federica Cuppone, MD, Fabiana Letizia Cecere, MD, Michele Milella, MD, Cecilia Nisticò, MD, Francesco Cognetti, MD,
More informationThe Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (9), Page 5298-5303 Prognostic Value of Platelet to Lymphocyte Ratio in Patients with Non-Small Cell Lung Cancer Mohammad Sabry Elkady, Ghada
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationThe 5-year survival in patients with resected NSCLC ranges
SHIRISH M. GADGEEL Role of Chemotherapy and Targeted Therapy in Early-Stage Non Small Cell Lung Cancer Shirish M. Gadgeel, MD OVERVIEW On the basis of several randomized trials and meta-analyses, adjuvant
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationImpact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer
Impact of Large Tumor Size on Survival After Resection of Pathologically Node Negative (pn0) Non Small Cell Lung Cancer Shin-ichi Takeda, MD, Shimao Fukai, MD, Hikotaro Komatsu, MD, Etsuo Nemoto, MD, Kenji
More informationRisk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer
Gastric Cancer (2013) 16:133 139 DOI 10.1007/s10120-012-0158-1 ORIGINAL ARTICLE Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer Toru Aoyama Takaki Yoshikawa Tsutomu
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationNode-Negative Non-small Cell Lung Cancer
ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationRetrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients
(2017) 1(1): 16-24 Mini Review Open Access Retrospective analysis of Gefitinib and Erlotinib in EGFR-mutated non-small-cell lung cancer patients Chao Pui I 1,3, Cheng Gregory 1, Zhang Lunqing 2, Lo Iek
More informationLung cancer is one of the leading causes of death in most
ORIGINAL ARTICLE Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD,* Etsuo Miyaoka, PhD, Hisao Asamura, MD, PhD,
More informationRESEARCH ARTICLE. Masaki Tomita 1, Takanori Ayabe 1, Eiichi Chosa 1, Naohiro Nose 1, Kunihide Nakamura 2 * Abstract. Introduction
RESEARCH ARTICLE Prognostic Significance of a Tumor Marker Index Based on Preoperative Serum Carcinoembryonic Antigen and Krebs von den Lungen-6 Levels in Non-Small Cell Lung Cancer Masaki Tomita 1, Takanori
More informationTreatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER: ACCP GUIDELINES Treatment of Non-small Cell Lung Cancer Stage I and Stage II* ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Walter J.
More informationAdjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review)
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer (Review) Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, Aupérin A, Le Chevalier T, Stephens RJ, Arriagada
More informationLung cancer is now a major cause of death in developed
Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationA Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma
Jpn J Clin Oncol 26;36(2)69 75 doi:.93/jjco/hyi228 Original Articles A Correlation between EGFR Gene Mutation Status and Bronchioloalveolar Carcinoma Features in Japanese Patients with Adenocarcinoma Hiroshi
More informationPrognosis of non-small-cell lung cancer patients with positive pleural lavage cytology
Interactive CardioVascular and Thoracic Surgery 20 (2015) 777 782 doi:10.1093/icvts/ivv047 Advance Access publication 11 March 2015 ORIGINAL ARTICLE THORACIC Cite this article as: Nakao M, Hoshi R, Ishikawa
More informationMore than 75,000 procedures in the United States and 3000
General Thoracic Surgery Sedrakyan et al Postoperative chemotherapy for non small cell lung cancer: A systematic review and meta-analysis Artyom Sedrakyan, MD, PhD a,b Jan van Der Meulen, PhD a,b Ken O
More informationPrognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer
Yonago Acta Medica 2017;60:213 219 doi: 10.24563/yam.2017.12.001 Original Article Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer Yasuaki Kubouchi,
More informationPrognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution
Maruyama et al General Thoracic Surgery Prognostic value of visceral pleural invasion in resected non small cell lung cancer diagnosed by using a jet stream of saline solution Riichiroh Maruyama, MD Fumihiro
More informationClinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer
Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More informationRelevance of an extensive follow-up after surgery for nonsmall cell lung cancer
ORIGINAL ARTICLE LUNG CANCER Relevance of an extensive follow-up after surgery for nonsmall cell lung cancer Delphine Gourcerol 1,2, Arnaud Scherpereel 1,2, Stephane Debeugny 3, Henri Porte 2,4, Alexis
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationLung cancer is the leading cause of cancer-related death in
ORIGINAL ARTICLE Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice Christophe Massard, MD,* Pierre Tran Ba Loc, MD, Vincent Haddad, MS, Jean-Pierre Pignon, MD, Philippe Girard,
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationLong-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer
ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*
More informationSurgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classi cation and its time trend q
European Journal of Cardio-thoracic Surgery 18 (2000) 147±155 www.elsevier.com/locate/ejcts Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classi
More informationSurgery combined with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: a phase II study
/, 2017, Vol. 8, (No. 63), pp: 107089-107095 Surgery combined with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: a phase II study Bo Deng 1,*, Tianyu Sun 1,*, Bo Tang 1,*, Shaolin
More informationLung cancer is the leading cause of cancer death worldwide.
ORIGINAL ARTICLE A Randomized Phase II Study of a Combination of Docetaxel and S-1 versus Docetaxel Monotherapy in Patients with Non-small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy
More information